In fact, in the absence of commercially available bona fide anti-CXCL14 blocking antibodies, we cannot discriminate between a purely direct and a partly indirect mechanism of action for CXCL14 on glioblastoma cells. The gene discussed is CXCL14; the disease is glioblastoma.